Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Nat Genet. 2013 Feb;45(2):180-5. doi: 10.1038/ng.2509. Epub 2013 Jan 13.
A 44-year old woman with recurrent solitary fibrous tumor (SFT)/hemangiopericytoma was enrolled in a clinical sequencing program including whole-exome and transcriptome sequencing. A gene fusion of the transcriptional repressor NAB2 with the transcriptional activator STAT6 was detected. Transcriptome sequencing of 27 additional SFTs identified the presence of a NAB2-STAT6 gene fusion in all tumors. Using RT-PCR and sequencing, we detected this fusion in all 51 SFTs, indicating high levels of recurrence. Expression of NAB2-STAT6 fusion proteins was confirmed in SFT, and the predicted fusion products harbor the early growth response (EGR)-binding domain of NAB2 fused to the activation domain of STAT6. Overexpression of the NAB2-STAT6 gene fusion induced proliferation in cultured cells and activated the expression of EGR-responsive genes. These studies establish NAB2-STAT6 as the defining driver mutation of SFT and provide an example of how neoplasia can be initiated by converting a transcriptional repressor of mitogenic pathways into a transcriptional activator.
一位 44 岁的女性患有复发性孤立性纤维瘤(SFT)/血管外皮细胞瘤,她参加了一个包括全外显子组和转录组测序的临床测序项目。检测到转录抑制剂 NAB2 与转录激活剂 STAT6 的基因融合。对 27 例额外的 SFT 的转录组测序发现,所有肿瘤均存在 NAB2-STAT6 基因融合。使用 RT-PCR 和测序,我们在所有 51 例 SFT 中均检测到该融合,表明复发率很高。在 SFT 中证实了 NAB2-STAT6 融合蛋白的表达,并且预测的融合产物具有 NAB2 的早期生长反应(EGR)结合域融合到 STAT6 的激活域。NAB2-STAT6 基因融合的过表达诱导培养细胞的增殖,并激活 EGR 反应基因的表达。这些研究确立了 NAB2-STAT6 为 SFT 的明确驱动突变,并提供了一个例证,说明如何通过将有丝分裂途径的转录抑制剂转化为转录激活剂来引发肿瘤发生。